Difference between revisions of "Thrombocytopenia in liver disease"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
|||
Line 1: | Line 1: | ||
− | {| class="wikitable" style="text-align:center; width: | + | {| class="wikitable" style="text-align:center; width:100%;" |
− | !colspan="2" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Section editor''' | + | ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#31a354" |'''Page editor''' |
+ | ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#31a354" |'''Section editor''' | ||
|- | |- | ||
+ | | style="background-color:#F0F0F0; width:15%" |[[File:Mistryrh.jpeg|frameless|upright=0.3|center]] | ||
+ | | style="width:35%" |<big>Ronak H. Mistry, DO<br>Vanderbilt University<br>Nashville, TN</big><br>[https://www.linkedin.com/in/ronak-mistry-0482864b/ LinkedIn] | ||
|style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] | |style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] | ||
|style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Vanderbilt University<br>Nashville, TN</big> | |style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Vanderbilt University<br>Nashville, TN</big> |
Revision as of 14:57, 13 October 2021
Page editor | Section editor | ||
---|---|---|---|
Ronak H. Mistry, DO Vanderbilt University Nashville, TN |
Benjamin Tillman, MD Vanderbilt University Nashville, TN |
See the thrombocytopenia reference page for general definitions and workup recommendations.
2 regimens on this page
2 variants on this page
|
Thrombocytopenia in liver disease with planned procedure
Avatrombopag monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Terrault et al. 2018 (ADAPT-1) | Phase III (E-esc) | Placebo | Superior primary endpoint |
Terrault et al. 2018 (ADAPT-2) | Phase III (E-esc) | Placebo | Superior primary endpoint |
Growth factor therapy
- Avatrombopag (Doptelet) as follows:
- Platelet count less than 40 x 109/L: 60 mg PO once per day on days 1 to 5
- Platelet count at least 40 and less than 50 x 109/L: 40 mg PO once per day on days 1 to 5
Procedure days were days 10 to 13
References
- ADAPT-1: Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018 Sep;155(3):705-718. Epub 2018 May 17. link to original article PubMed NCT01972529
- ADAPT-2: Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018 Sep;155(3):705-718. Epub 2018 May 17. link to original article PubMed NCT01976104
Lusutrombopag monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
(L-PLUS 1/L-PLUS 2) | Phase III (E-esc) | Placebo | Superior primary endpoint |
Note: there are no apparent publications of these trials, to date.
Growth factor therapy
- Lusutrombopag (Mulpleta) 3 mg PO once per day on days 1 to 7
7-day course
References
Placebo
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Terrault et al. 2018 (ADAPT-1/ADAPT-2) | Phase III (C) | Avatrombopag | Inferior primary endpoint |
(L-PLUS 1/L-PLUS 2) | Phase III (C) | Lusutrombopag | Inferior primary endpoint |
No active treatment.
References
- ADAPT-1/ADAPT-2: Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018 May 17. [Epub ahead of print] link to original article PubMed